Outlook for Generic Pharmaceuticals Contract Manufacturing Market: Key Developments and Future Strategies to 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Outlook for the Generic Pharmaceuticals Contract Manufacturing Market Heading Into 2029?
The market size for generic pharmaceuticals contract manufacturing has seen substantial growth recently. The market is projected to expand from $62.30 billion in 2024 to $66.82 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.3%. This growth trajectory during the historical phase is linked to various factors including a spike in the demand for affordable medications, elevated healthcare spending in developing nations, an increase in patent expiries of branded medications, more outsourcing from pharmaceutical firms, and the escalating incidence of chronic illnesses.
Expectations are high for the generic pharmaceuticals contract manufacturing market size to experience considerable expansion in the coming years. By 2029, it is projected to reach $87.59 billion with a compound annual growth rate (CAGR) of 7.0%. This growth for the forecasted period is primarily due to several factors: increased emphasis on specialty generics, enhanced government backing for usage of generic medications, widening access to healthcare in emerging markets, increased investments in contract manufacturing facilities, and an escalating need for adaptable and scalable production solutions. The forecast period will also witness several trends including advancements in production automation, enhanced quality control technologies, the creation of intricate generic formulations, innovations in drug delivery systems, and improvements in continuous manufacturing processes.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25771&type=smp
Which Factors Are Pushing The Generic Pharmaceuticals Contract Manufacturing Market Forward?
The upward trend in biosimilars requirement is likely to stimulate the expansion of the generic pharmaceuticals contract manufacturing sector in the future. Biosimilars, which are biologic medical substances that are considerably similar to already sanctioned reference biologics, exhibit no clinically significant variances in terms of safety, purity, or effectiveness. The growing demand for biosimilars primarily originates from their ability to offer affordable alternatives to costly biologic drugs, thereby rendering complex treatments more accessible to both patients and healthcare systems. Contract manufacturing within the generic pharmaceutical realm facilitates biosimilars, bringing about affordable large-scale production expertise and providing crucial regulatory knowledge, which hastens market penetration and ensures a steady quality. For example, Cardinal Health Inc., a US-based healthcare firm, reported in February 2022 that as of January that year, the US had 33 biosimilars accredited by the Food and Drug Administration (FDA), of which 21 were available in the marketplace. Additionally, by January 2023, the count of FDA-endorsed biosimilars had escalated to 40, with 25 being commercially accessible. As such, the surging demand for biosimilars is indeed catalyzing the growth of the generic pharmaceuticals contract manufacturing market.
Which Segment Held The Largest Share In The Generic Pharmaceuticals Contract Manufacturing Market In 2025?
The generic pharmaceuticals contract manufacturing market covered in this report is segmented –
1) By Drug Type: Branded Generics, Unbranded Generics
2) By Product Type: Pharmaceutical Active Pharmaceutical Ingredients, Formulations, Capsules, Tablets, Injectables
3) By Route Of Administration: Oral, Parenteral, Topical, Other Routes Of Administration
4) By Application: Oncology, Immunology, Antidiabetic, Neurology, Anticoagulants, Cardiovascular, Respiratory, Pain, Human Immunodeficiency Virus Antivirals
5) By End-User Industry: Pharmaceutical Companies, Contract Research Organizations, Biotechnology Companies, Generic Drug Manufacturers
Subsegments:
1) Branded Generics: Contract Development of Branded Formulations, Branded Generic Tablet Manufacturing, Branded Injectable Manufacturing, Packaging and Labeling for Branded Generics, Regulatory Support For Branded Generics
2) By Unbranded Generics: Bulk Manufacturing of Off-Patent Active Pharmaceutical Ingredients, Generic Tablet Or Capsule Production, Parenteral Or Injectable Generic Manufacturing, Cost-Efficient Packaging for Unbranded Products, Licensing And Tech Transfer for Generic Products
How Are Key Trends Driving Expansion In The Generic Pharmaceuticals Contract Manufacturing Industry?
Leading firms that are part of the generic pharmaceutical contract manufacturing market are broadening their range of services by creating dedicated subsidiaries, in order to address the increasing need for outsourced manufacturing and development. By forming these dedicated subsidiaries, companies can efficiently manage the production of active pharmaceutical ingredients (APIs), ensuring adherence, flexibility, and smooth functioning throughout the medicine development process. For instance, in July 2025, Lupin, a generic pharmaceutical company based in India, inaugurated its new branch, Lupin Manufacturing Solutions (LMS), to make its entry into the contract development and manufacturing organization (CDMO) market. This specialized division is intended to aid in the development, production, and sale of APIs to worldwide pharmaceutical collaborators. Guided by a leadership team well-versed in biotech and pharma, the subsidiary is equipped to offer superior contract services, thereby enabling pharmaceutical firms to expedite their market introduction while upholding regulatory standard and cost-effectiveness.
Which Organizations Are Driving Progress In The Generic Pharmaceuticals Contract Manufacturing Industry?
Major companies operating in the generic pharmaceuticals contract manufacturing market are Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Fresenius Kabi AG, WuXi AppTec Co. Ltd., Aurobindo Pharma, Cipla Limited, Recipharm AB, Siegfried Holding AG, Curia Global Inc., Torrent Pharmaceuticals Limited., Piramal Pharma Solutions, Laurus Labs Limited., Cambrex Corp., Pfizer CentreOne, Syngene International Ltd., Wockhardt Ltd., Alcami Corp. Inc, Neuland Laboratories Limited., Panacea Biotec Ltd., Jubilant Generics Ltd.
Get The Full Report Here:
Which Region Is Expected To Experience The Highest Growth In The Generic Pharmaceuticals Contract Manufacturing Industry?
North America was the largest region in the generic pharmaceuticals contract manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generic pharmaceuticals contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=25771&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
